Development and Validation of a Computational Method for Assessment of Missense Variants in Hypertrophic Cardiomyopathy  by Jordan, Daniel M. et al.
ARTICLE
Development and Validation of a Computational
Method for Assessment of Missense Variants
in Hypertrophic Cardiomyopathy
Daniel M. Jordan,1,2,8 Adam Kiezun,1,8 Samantha M. Baxter,3,8 Vineeta Agarwala,2,3 Robert C. Green,4,5,6
Michael F. Murray,1 Trevor Pugh,3,6 Matthew S. Lebo,3,6 Heidi L. Rehm,3,7 Birgit H. Funke,3,7,*
and Shamil R. Sunyaev1,*
Assessing the significance of novel genetic variants revealed by DNA sequencing is a major challenge to the integration of genomic tech-
niques with medical practice. Many variants remain difficult to classify by traditional genetic methods. Computational methods have
been developed that could contribute to classifying these variants, but they have not been properly validated and are generally not
considered mature enough to be used effectively in a clinical setting. We developed a computational method for predicting the effects
of missense variants detected in patients with hypertrophic cardiomyopathy (HCM). We used a curated clinical data set of 74 missense
variants in six genes associated with HCM to train and validate an automated predictor. The predictor is based on support vector regres-
sion and uses phylogenetic and structural features specific to genes involved in HCM. Ten-fold cross validation estimated our predictor’s
sensitivity at 94% (95% confidence interval: 83%–98%) and specificity at 89% (95% confidence interval: 72%–100%). This corresponds
to an odds ratio of 10 for a prediction of pathogenic (95% confidence interval: 4.0–infinity), or an odds ratio of 9.9 for a prediction of
benign (95% confidence interval: 4.6–21). Coverage (proportion of variants for which a prediction was made) was 57% (95% confidence
interval: 49%–64%). This performance exceeds that of existing methods that are not specifically designed for HCM. The accuracy of this
predictor provides support for the clinical use of automated predictions alongside family segregation and population frequency data in
the interpretation of new missense variants and suggests future development of similar tools for other diseases.Introduction
DNA sequencing is quickly becoming the method of
choice for clinical genetic diagnostics. The improvement
in clinical sensitivity that sequencing provides over geno-
typing platforms is invaluable, especially in disorders that
show locus and allelic heterogeneity. However, there are
also important challenges presented by the use of DNA
sequencing, including the difficulty of interpreting novel
sequence variants. There is currently little standardization
of variant classification in the genetics community. Most
clinics use a combination of traditional genetic methods
relying on segregation with the disease in families,
frequency in controls, biochemical characterization, and
evolutionary conservation at the variant position.1 This
manual classification process is time consuming and
requires significant expert knowledge. More frustratingly,
it often fails to produce a classification at all: variants
with incomplete or conflicting data are routinely classified
as variants of unknown significance (VUSs), and no confi-
dent classification is reported to the patient or the referring
physician. In some genes, these VUSs comprise as many as
one-quarter to one-half of all reported variants.2 This
problem is only getting worse. As next-generation
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The Americause, the volume of novel variants is expected to expand by
several orders of magnitude. The genetics community
must therefore begin to develop robust automated
methods to classify novel variants accurately.
There currently exist several computational tools for pre-
dicting the functional effects of genetic variants.3–5
However, these tools in general were not designed for clin-
ical use, have not been rigorously tested on individual
genes or diseases, and have not undergone any kind of vali-
dation against well-curated data sets. Therefore, the sensi-
tivities and specificities of these predictors are in general
ill-defined. This lack of proper validation has created the
perception among medical professionals that automated
predictors cannot be trusted.6 Consequently, although
most geneticists are familiar with these tools, the predic-
tions they produce are typically not formally included in
clinical variant classification methods and are therefore
not communicated to physicians via clinical reports.
Several studies have attempted to address this problem
by validating existing predictors against known disease-
causing variants, largely arriving at the conclusion that
these methods are not yet mature enough for clinical
use.6–8
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from the ground up with clinical use in mind and are de-
signed, demonstrated, and validated using variants classi-
fied according to clinical criteria. Examples of such pipe-
lines include the classification procedure currently in use
at the Laboratory for Molecular Medicine (LMM), a clinical
diagnostic laboratory in the U.S., and the integrated evalu-
ation of BRCA gene variants that developed from the work
of Goldgar et al.9 However, fully automated computational
predictors are not currently designed in this way.We there-
fore set out to test whether this methodology could
successfully create an automated predictor that would be
useful to medical professionals as a tool for classifying
novel missense variants. We chose to target one specific
disease and a limited number of genes in which disease-
causing variants might be found so that we would be
able to generate a high-quality set of manually classified
missense variants to use as the gold standard for training
and validating our predictions. We also hoped that
focusing on a limited number of functionally related genes
would allow us to identify common features of these genes
and commonmechanisms of disease in these genes, which
would help us to make our predictor more accurate.
The disease we chose was hypertrophic cardiomyopathy
(HCM [MIM 192600]), an autosomal dominant disease of
the myocardium (heart muscle) with an incidence of
roughly one in 500 individuals and a largely genetic
basis.10 Variants in over 20 genes are associated with
HCM, with over 900 unique variants reported in the liter-
ature, and sequencing of many of these genes can be
ordered for clinical testing in CLIA-approved laboratories.
The vast majority of pathogenic variants are found in eight
genes that encode for units of the cardiac sarcomere,
a contractile protein complex in the heart: b-cardiac
myosin heavy chain (MYH7 [MIM 160760]), cardiac actin
(ACTC1 [MIM 102540]), cardiac troponin T (TNNT2
[MIM 191045]), a-tropomyosin (TPM1 [MIM 191010]),
cardiac troponin I (TNNI3 [MIM 191044]), cardiac
myosin-binding protein C (MYBPC3 [MIM 600958]), and
the myosin light chains (MYL2 [MIM 160781] and MYL3
[MIM 160790]). Sequencing of these genes yields a high
number of novel variants, mainly because of the high
prevalence of private familial variants. Roughly 50%
of probands tested have a disease-causing variant in one
of these genes, and approximately 80% of those are
in MYH7 and MYBPC3 (H.L.R., unpublished data).11
Missense variants represent nearly all such variants de-
tected in MYH7 and 35% of those in MYBPC3. Missense
variants exerting dominant negative effects on the sarco-
mere structure represent the vast majority of all variants.
The notable exception is MYBPC3, where missense vari-
ants constitute only 35% of all variants, the remainder
being splice, nonsense, or frameshift variants leading to
loss of function. At the time of this study, the LMM had
identified over 700 variants in HCM-related genes over
5 years of testing, over half of which were novel at the
time of reporting and over half of which were missense
changes. We performed a systematic manual classification184 The American Journal of Human Genetics 88, 183–192, Februaryof these variants, producing a final data set of 74 missense
variants with extremely confident manual classifications.
Using these 74 variants as our gold standard, we then set
out to develop and validate a computational method that
could predict the pathogenicity of any variant in these
six genes.Material and Methods
We created a computational method to predict the pathogenicity
of a novel variant in any of the six genes we chose to screen for
HCM mutations. Our method, like other existing methods12–16
and, particularly, the recently developed algorithm PolyPhen-
2,17 integrates phylogenetic and structural information from
several heterogeneous sources with a probabilistic classifier.
However, unlike these methods, it exploits the narrow focus on
six specific genes known to contain variants that cause the disease
to improve the prediction strategy significantly. Also unlike these
methods, it uses variants classified according to clinical criteria of
pathogenicity to train the probabilistic classifier. The selection and
classification of these variants, the features used for classification,
and the training and validation of the classifier are all described
below. This study was performed under an institutional-review-
board-approved protocol through Partners Healthcare System.
Selection of Target Genes
HCM is caused primarily by variants in eight genes encoding
protein subunits of the cardiac sarcomere. We initially attempted
to use all eight genes to develop our predictor. However, after con-
structing our data set (see Manual Classification of HCM Variants
below), we examined the distribution of variants and found that
the final data set contained no variants in ACTC1 and only one
in MYL3. We discarded these two genes and built our classifier
around the remaining six (MYH7, TNNT2, TPM1, TNNI3,
MYPC3, and MYL2).
Manual Classification of HCM Variants
We relied on LMM’s standard variant-assessment pipeline to create
our data set of manually classified variants. To ensure unbiased
training and testing of our computational method, we excluded
from manual classification information that was accessible to
the method such as evolutionary conservation or structural data,
even though this information is currently used in the pipeline.
Each variant recieved a classification of pathogenic, likely patho-
genic benign, likely benign, or VUS. The basic decision process
we used is described below and shown in Figure 1.
Pathogenic
Variants with a minimum of five informative meioses supporting
familial cosegregation with HCM, absent in healthy controls, and/
or having strong functional data are classified as pathogenic. In
HCM, informative meioses typically only include individuals
who are positive for both phenotype and genotype. This level of
stringency is required because of the highly variable expressivity
and reduced penetrance, which make individuals without the
phenotype largely uninformative, regardless of their genotype.
Likely Pathogenic
The minimum requirement to classify a variant as likely patho-
genic is absence from race-matched controls or a large cohort of
race-matched probands. The LMM has previously sequenced
sarcomere genes in over 1000 HCM probands of European11, 2011
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Figure 1. Process Used to Classify Variants at the LMM
This process is described in detail in Material and Methods. We treat the pathogenic, benign, and likely benign categories as high-confi-
dence classifications for the purposes of training the automatic classifier.
Figure 2. Distribution of Variant Pathogenicity
We categorized 350missense variants in six genes according to the
criteria described in Figure 1. The three categories pathogenic,
benign, and likely benign were treated as high-confidence classifi-
cations and used as training data for our classifier (enumerated in
Table S1).ancestry. Absence from this cohort was accepted in lieu of healthy
control data because it serves to set a maximum population
frequency of one per the total number of probands tested. Novel
variants detected in minority populations are therefore often
classified as VUSs because of the lack of control cohorts or large
proband datasets.
Benign or Likely Benign
Variants that are frequent in the general population (at least 3%)
are classified as benign. Variants present in controls at frequencies
below 3% and without other suspicion for pathogenicity are
classified as likely benign.
VUS
This class commonly includes variants for which there is insuffi-
cient evidence to classify the variant in any of the other four cate-
gories, or variants for which the evidence is conflicting.
Figure 2 shows the distribution of variants by the classification
category in our database.
After applying these criteria to the complete set of variants
collected by LMM, we filtered the resulting data set to exclude un-
confident predictions. We excluded variants in the likely-patho-
genic category because we considered the classification for this
category to be not stringent enough. We also excluded variants
in the VUS category because this category carries no clinical or bio-
logical significance. This left us with 41 pathogenic variants,
which we treated as truly pathogenic, and seven benign and 26
likely benign variants, all of which we treated as truly benign.
These 74 variants became our gold standard for validation of our
predictor. The complete list of 74 variants is shown in Table S1.
There is a possibility that the manual method of variant classifi-
cation may have selected variants resulting in the most severe
phenotypes, such as those seen in early-onset cases, which may
reduce the utility of our classifier for less severe variants. To inves-
tigate this possibility, we used the age at which an individual was
tested as a proxy for age at onset. The distribution of ages of all
probands tested is roughly trimodal with clear peaks at < 1 and
15 years of age and a broad distribution centered around 50 years
of age (Figure S1). The distribution of pathogenic variants in this
population follows a similar distribution with pathogenic variantsThe Americadetected across a wide range of age groups tested. If we were indeed
selecting for only the most severe, early-onset phenotypes, we
would expect pathogenic variants to be overrepresented in
newborns and teenagers and to be absent in late-onset cases.
This does not appear to be the case, and we are confident that
our training set does not only consist of pathogenic variants
that lead to high penetrance, early-onset disease.Predictive Features
We used four features in the final predictor. These features are
described below.
PolyPhen-2 Prediction
Our first feature was a prediction made by the existing method
PolyPhen-2.17 PolyPhen-2’s predictions integrate several sources
of phylogenetic and structural information using machine
learning. Its output represents a general-purpose predictionn Journal of Human Genetics 88, 183–192, February 11, 2011 185
made without knowledge of the specific disease under consider-
ation. The PolyPhen-2 software reports a score ranging from
0 (neutral) to 1 (damaging), which represents the confidence of
its internal classifier. We used this integrated score as a single
feature in our predictor.
MrBayes Substitution Rate Score
Our second feature was the rate of evolution for each site in each
gene.We computed this using theMarkov chainMonteCarlo algo-
rithm in the MrBayes software package.18 This score took several
days of computer time to calculate for all six genes and would not
have been feasible to calculate for a genome-wide data set.
Examples of the MrBayes instruction files we used are available
as Figure S2. We used a function that infers site-specific evolution
rates and includes them in the program’s output. MrBayes reports
the rate at positions with insufficient alignment depth as 1.000, so
all scores of exactly 1.000 were treated as missing data.We normal-
ized this rate so that the mean rate for each gene was 1.000.
Coiled-Coil Score
Our next two features took advantage of specific properties of the
six target genes. Four of the six target proteins had significant
coiled-coil regions: MYH7, TNNI3, TNNT2, and TPM1. We used
the COILS2 software to predict the tendencies of the wild-type
and mutant sequences to form coiled coils.19,20 Variants that
significantly change the coiled-coil tendency of the sequence are
likely to interfere with protein function.
For each of the four proteins, we downloaded annotations from
SMART to determine the locations of coiled-coil regions.21 For any
variant in a coiled-coil region, we ran COILS2 on both the wild-
type and variant sequences of the coiled-coil region that contained
the variant. COILS2 outputs a score indicating coiled-coil
tendency for each residue in the input sequence with each score
depending on the entire sequence. The feature we used in the final
predictor was the magnitude of the largest single-residue change.
Protein Structure Comparison Score
Four of the six target proteins are contractile proteins studied in
multiple conformations (MYH7 andMYL2 in ATP, ADP, and nucle-
otide-free states; TNNI3 and TNNT2 in Ca2þ-activated and Ca2þ-
free states). For these four proteins, we measured the motion of
each residue between the two conformations. Highly mobile resi-
dues were considered functionally important to the conforma-
tional change, whereas highly immobile residues were considered
structurally important. Intermediately mobile residues were
scored as unimportant. We measured the size of each residue’s
motion by comparing the displacement of the residue to the ex-
pected probability distribution of displacements under random
thermal motion.
We used two sets of structures to compute this score. One was
a set of six structures of a three-chain scallop myosin complex,
consisting of the myosin heavy chain (corresponding to MYH7
in human heart muscle) and the two myosin light chains (corre-
sponding to MYL2 and MYL3 in human heart muscle).22,23 One
of these structures was not bound to a nucleotide (PDB ID
1KK7), two were bound to ADP analogs (PDB ID 1KK8 and
1B7T), and three were bound to ATP analogs (PDB ID 1KQM,
1KWO, and 1L2O). The other set of structures was a pair of struc-
tures of a three-chain chicken troponin complex, consisting of
troponin I (corresponding to TNNI3 in human heart muscle),
troponin T (corresponding to TNNT2 in human heart muscle),
and troponin C (corresponding to TNNC1 in human heart
muscle).24 One of these structures was activated by calcium ions
(PDB ID 1YTZ), and the other had no calcium bound to it (PDB
ID 1YV0).186 The American Journal of Human Genetics 88, 183–192, FebruaryWe performed pairwise comparisons between structures that
represented the same molecule in different biological states. Pairs
of structures that represented the same biological state (such as
1KK8 and 1B7T, which both represent the ADP-bound state of
myosin) were excluded under the assumption that differences
between these structures would represent differences in the exper-
imental preparation rather than a meaningful conformational
change. We aligned each pair of structures with LovoAlign and
measured the displacement between the a carbons of correspond-
ing residues.25
The variance in the position of an atom in a crystal structure is
given by s2 ¼ B=8p2, where B is the crystallographic temperature
factor for the atom. We computed this variance for the a carbon
of each residue, estimating B as the average of the reported temper-
ature factor for that atom across the two crystal structures.We used
Student’s t test to compare the squared displacement of the atom
with its expected variance. This produced a p value for the
observed squared displacement, with numbers close to 0 represent-
ing motion much smaller than expected, numbers close to 1 rep-
resenting motion much larger than expected, and numbers close
to 0.5 representing the expected amount of motion. Finally, scores
below 0.5 were subtracted from 1, so that a higher score would
consistently represent a more important residue.
The human genes were aligned to the structures with BLAST.
Each residue in the human sequence was scored the same as the
residue it aligned to. Residues that did not align to the structures
were not given a score. Only 84 human residues failed to align
to the structures, which represent 3.2% of all positions in the
four proteins to which we applied this score.
Multiple Sequence Alignments
Both PolyPhen-2 and the MrBayes score described above use
comparative sequence analysis as a source of phylogenetic infor-
mation. These methods take as input aligned sequences of
multiple homologous proteins, and their predictive values criti-
cally depend on the quality of the multiple sequence alignments
used. Existing computational methods, including PolyPhen-2
and SIFT, rely on automated pipelines to construct multiple
sequence alignments.12,13,17 We used the standard automated
alignment pipeline provided by PolyPhen-2 but, because we
only needed to construct six alignments, we were able to inspect
and adjust each alignment manually.
We noticed in our manual inspection that some of the auto-
mated alignments were of very poor quality. The worst alignments
were for the two genes,MYBPC3 andMYH7, that weremost highly
represented in our data set. These genes have numerous homologs
at the domain level, arising from the multiple immunoglobulin
domains of MYBPC3 and the highly conserved myosin motor
domain of MYH7, and the multiple sequence alignments
produced with automatically selected homologs are therefore of
poor quality. We created new alignments for MYBPC3 and MYH7
by manually removing problematic sequences from the automat-
ically generated alignments. This approach allowed us to tune the
alignments manually while still taking advantage of PolyPhen-2’s
automatic filtering of poor alignments and incorrect sequences.
The alignments were very deep to begin with, allowing us to re-
move a large number of sequences without having the alignments
become too shallow to use.
The sequences we removed from the alignments were those that
appeared to have only domain-level homology to the target
sequences and/or did not appear to have a sufficiently similar
function to the target sequences. In other words, we attempted11, 2011
to create an alignment forMYBPC3 that consisted only of forms of
myosin-binding protein C from various tissues and organisms and
an alignment for MYH7 that consisted only of forms of myosin
heavy chain from various tissues and organisms. The resulting
alignments were used as input to the PolyPhen-2 classifier and
to MrBayes. The sequences used are listed in Tables S3–S6, and
the resulting alignments are shown in Figure S3.
Training and Validation
We trained the classifier on the manually curated set of 74
missense variants in six genes. For each variant in the training
set, we computed the four features described above (PolyPhen-2
prediction, MrBayes substitution rate score, coiled-coil score, and
protein structure comparison score). The values of each feature
for each variant can be found in Table S2. The training algorithm
(Figure S4) aims to maximize accuracy of classification while
keeping the required level of coverage. To avoid overfitting, the
training algorithm uses 10-fold cross validation (Figure S5). This
method splits the training data into ten parts (six parts of seven
samples, four parts of eight samples), trains the classifier on nine
training parts, and tests it on the remaining testing part. It then
repeats the split-train-test procedure ten times, each time with
a different part of the data used for testing. In order to account
for the different results that would be produced by using different
random divisions of the data in this process, we ran 1000 itera-
tions of 10-fold cross validation, using a different random division
of the data each time. We also tested the final classifier using
a leave-one-out cross-validation strategy. The classifier assigns
a prediction of pathogenic, benign, or no call to each variant. The
no call prediction is given to variants the classifier cannot predict
confidently. This category is included so that we can improve
the accuracy (fraction of variants predicted correctly) of our confi-
dent predictions by sacrificing coverage (fraction of variants pre-
dicted to be either pathogenic or benign).2
Feature Selection
To verify that each of these four features made an important
contribution, we constructed four incomplete classifiers, each
one missing one of the four features. We performed validation
on each of these classifiers as described above, and performed
a random permutation test to show that the complete classifier
had higher accuracy than each of the incomplete classifiers. We
performed 106 permutations, so that the minimum p value we
could find was 106. Out of our four features, only the Poly-
Phen-2 score had a one-sided p value greater than this minimum,
with p ¼ 0:0544; the other three features all had one-sided p values
of less than 106. We also performed the same test to establish that
using manual alignments instead of automatic alignments
improved the score and found that it did with a one-sided p value
of less than 106. Figure 5 shows the distributions of accuracies for
each set of features in 1000 runs of cross validation.
In addition to the four features in our final classifier, we also
tried replacing PolyPhen-2 with the similar tools SIFT and
PANTHER.12,13,26,27 We found that each performed comparably
to PolyPhen-2, though the classifier with PolyPhen-2 performed
very slightly better than either, again with one-sided p values
less than 106. Interestingly, though PolyPhen-2, SIFT, and
PANTHER were each far more informative individually than any
other single feature, each made by far the least individual contri-
bution to the full four-feature classifier that included it. Evidently,
the other three features together contain enough information to
make the PolyPhen-2, SIFT, or PANTHER score largely redundant.The AmericaWe also investigated the effect each feature had on coverage.
This was of particular concern for the structure pair score and
the coiled-coil score, each of which is missing entirely from several
genes and regions, which could reduce the predictor’s ability to
make confident classifications in these regions. We found that
both the structure pair score and the coiled-coil score actually
increase the coverage, whereas neither of the other features has
a significant effect. This suggests that it is rare for a variant that
could be scored confidently with the PolyPhen and substitution-
rate scores to be demoted to no call because it is missing one or
both of the other features. In other words, the coiled-coil and
structure pair scores tend to increase confidence where they are
present rather than decreasing it where they are absent.
Results
The Prediction Method
We created an automated method to predict the pathoge-
nicity of missense variants in six genes known to contain
variants that cause HCM. In designing this predictor, we set
out to take advantage of the fact that we were focusing on
a small set of functionally related genes to improve our
predictions.We identified twoways to accomplish this: first,
by exploiting unique structural and biochemical properties
of the six target genes and, second, by applying more
rigorous methods that would be difficult to implement for
large numbers of genes. With these principles in mind, we
developed a total of three predictive features, which we
used inconjunctionwith theexistingPolyPhen-2classifier.17
Two of these features reflect specific structural properties of
sarcomeric proteins. One scores the effect of amino acid
change on coiled-coil regions, whereas the other scores the
importanceof themutated residue to functionally important
conformational transitions in ATP and Ca2þ-binding
domains. The remaining feature is anestimated rate of evolu-
tion at the variant position. This feature was extremely time
consuming to compute and would not have been feasible to
apply to a genome-wide data set. It also was computed from
manually adjusted multiple sequence alignments of homol-
ogous sequences, which required human intervention to
produce. These same manually adjusted alignments were
alsousedas input toPolyPhen-2, improving its performance.
We combined these three features and the PolyPhen-2 score
usingmachine learningwithour setof 74manually classified
variants as a training set. The complete method is presented
graphically in Figure 3.
We also experimented with a small number of alterna-
tive features. The most notable among these were
a different estimate of the rate of evolution computed
with a genomic alignment of 46 vertebrate species, and
several of the individual phylogenetic scores used as
predictive features in PolyPhen-2. Addition of these
features did not improve the performance of the predictor.
Validation of the Method against Manually Classified
Variants
Given the small size of our gold standard data set (74 vari-
ants), the choice of training and validation method wasn Journal of Human Genetics 88, 183–192, February 11, 2011 187
Custom 
alignments
Coiled coil 
score
Protein 
structure pair 
score
PolyPhen-2 
prediction
MCMC 
estimation of 
evolution rate
Machine 
learning
10-fold 
cross-
validation
Clinical 
data
Figure 3. The Automated Prediction Process
For each variant, we computed four features and
combined them by a machine-learning classifier.
We trained this classifier on the high-confidence
variants classified with clinical data and validated
the classifier against the same data using 10-fold
cross validation.important. Because we had so few variants, it was not
feasible for us to use the simplest validation method of
splitting the data set in half and using one half for training
and the other for testing. Instead, we applied 10-fold cross
validation, which is the accepted procedure in such cases
(see Material and Methods). We ran this validation process
a total of 1000 times to obtain median results and confi-
dence intervals. Figure 4 shows the results of this valida-
tion for six different classifiers at different levels of
coverage and accuracy. We used the bottom row, high-
lighted in red, as our final classifier. The method predicts
each variant as pathogenic, benign, or no call, where the no
call result means that the predictor is not sufficiently confi-
dent to permit a prediction. The median accuracy for
covered variants for the most accurate classifier (the frac-
tion of correct predictions out of all pathogenic and benign
predictions when no call results are disregarded) was
92%, with a 95% confidence interval of 83%–98%
(Figure 5). The median coverage (the fraction of variants
that were predicted as either pathogenic or benign), was
57%, with a 95% confidence interval of 49%–64%; in other188 The American Journal of Human Genetics 88, 183–192, February 11, 2011words, the median classifier reported no call
for 43% of variants. The median sensitivity
for covered variants (the fraction of variants
manually classified as pathogenic that were
predicted as pathogenic, excluding those pre-
dicted as no call) was 94%, with a 95% confi-
dence interval of 83%–98%. The median
specificity for covered variants (the fraction
of variants manually classified as benign
that were predicted as benign, excludingthose predicted as no call) was 89%, with a 95% confidence
interval of 83%–98%. The median odds ratio for a predic-
tion of pathogenic (the odds of a pathogenic variant being
classified as pathogenic divided by the odds of a benign
variant being classified as pathogenic) was 10, with a 95%
confidence interval of 4.0–infinity (no upper bound could
be set because more than 5% of trials had no false posi-
tives). The median odds ratio for a prediction of benign
(the odds of a benign variant being classified as benign
divided by the odds of a pathogenic variant being classified
as benign) was 9.9, with a 95% confidence interval of
4.6–21. Leave-one-out cross validation also resulted in
highly similar estimates of all these quantities.
Comparison with General-Purpose Methods
Because our predictor bases its predictions in part on
predictions of the existing general-purpose method Poly-
Phen-2, we investigated whether our predictor was a signif-
icant improvement over the PolyPhen-2 predictor without
our modifications and other general-purpose methods. In
order to investigate this, we tested PolyPhen-2, SIFT, andFigure 4. Results of Cross Validation
Rows contain median 10-fold cross-validation
results for the gold standard data set at different
levels of coverage. Horizontal bars correspond to
different levels of coverage and median valida-
tion coverage and accuracy levels are indicated.
‘‘True Positives’’ are variants that were manually
classified as pathogenic and that our method pre-
dicted as pathogenic. ‘‘True Negatives’’ are variants
that were manually classified as benign or likely
benign and that our method predicted as benign.
‘‘False Positives’’ are variants that were manually
classified as benign’’ or likely benign but that
our method predicted as pathogenic. ‘‘False Nega-
tives’’ are variants that were manually classified
as pathogenic but that our method predicted as
benign. ‘‘Uncovered’’ are variantswithout a predic-
tion (no call). The bottom-most coverage level,
indicated in red, was used for our final predictor.
Figure 5. Feature Selection Experiment
Each column shows the distribution of accuracies
in 1000 runs of cross validation for a classifier
built with a different set of features: ‘‘all features’’
represents the final four-feature classifier with
manual alignments, ‘‘broken alignments’’ repre-
sents the four-feature classifier without auto-
matic alignments, and each of the other four
columns represents a three-feature classifier
missing the specified feature. Box plots show
lower and upper quartiles (50% confidence inter-
vals), and whiskers show 1.5 IQR ranges. The
addition of each feature appears to improve the
classifier, which is confirmed by a permutation
test.PANTHER on the same data set. We applied the same
10-fold cross-validation method with each of these three
scores as the only predictive feature. We found that all
three general-purpose scores had comparable performance
on this data set: PolyPhen-2’s median cross-validation
accuracy was 70% (95% confidence interval: 60%–77%),
SIFT’s was 74% (95% confidence interval: 64%–83%),
and PANTHER’s was 68% (95% confidence interval: 56%–
79%). All of these estimates are much lower than the accu-
racies reported for these methods, which may reflect
features of this data set. Our specialized predictor, on the
other hand, had a median accuracy of 92% (95% confi-
dence interval: 83%–98%), as reported above. A permuta-
tion test showed that all three general-purpose predictors
performed worse than our specialized predictor, with
one-sided p values of less than 106.Predictions for Variants without Confident
Classifications
The ultimate goal of our predictor is to provide accurate
predictions for variants that are not confidently classified
by manual methods. This will not be possible if there is
some systematic biological difference between the confi-
dent and unconfident classifications, such as a difference
in penetrance, severity, or mechanism of disease. To deter-
mine whether this is the case, we applied our method to
a low-confidence data set, the set of missense variants
that did not meet the confidence criteria to be manually
classified as truly pathogenic or benign (Figure 6). Of the
missense variants manually classified as likely pathogenic,
80% of those for which a prediction was made were pre-The American Journal of Humdicted as pathogenic. This is consistent
with the expectation that most of these
variants that were classified as likely patho-
genic are indeed pathogenic. It is also
consistent with the expectation that the
fraction of variants predicted as pathogenic
in this set is lower than the fraction of vari-
ants manually classified as confidently
pathogenic. Among variants manually clas-
sified as VUS, 70% of those for which
a prediction was made were predicted tobe pathogenic. Because these variants have been identified
in individuals diagnosed with HCM, there is a higher a pri-
ori likelihood that they are indeed pathogenic, although
we have no way of knowing what the true fraction should
be. The fraction of variants predicted to be pathogenic
remains lower in the VUS set than in the likely-pathogenic
set, which is consistent with what would be expected.
We also used the low-confidence data set to generate an
independent estimate of the predictor’s coverage. We
found that the predictor made a prediction for 60% of
low-confidence variants, which is well within the confi-
dence interval of 49%–64% for the estimated coverage
on the gold standard variants.Discussion
We developed and clinically validated an automated
method to predict the pathogenic effect of missense vari-
ants that might cause HCM. Unlike current commonly
used methods, our predictor has been validated against
high-confidence manually curated data. This enabled us
to estimate its specificity and sensitivity for the specific
task of predicting HCM mutations, which will allow its
predictions to be incorporated into clinical reports to
health care professionals as one piece of evidence support-
ing a variant classification. Although this tool adds little
for variants whose clinical significance is already sup-
ported by strong genetic and/or functional data, it will
add value for those variants that had little or no prospect
of ever being supported by solid family studies or large
scale healthy control studies. Importantly, our classifier isan Genetics 88, 183–192, February 11, 2011 189
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Figure 6. Results for Low-Confidence Data Set
Columns indicate, for each class of variants, the number of predic-
tions in predicted categories produced by the final classifier.particularly helpful for variants identified in minority pop-
ulations, where healthy control cohorts, one of the pillars
of traditional variant classification, are typically unavail-
able.
To maintain high accuracy, it was necessary to sacrifice
coverage, i.e., the proportion of variants for which a predic-
tion ismade.2 As shown in Figure 4, an increase in coverage
is accompanied by a rapid decline in accuracy. A method
attempting to predict every variant as either pathogenic
or benign could not achieve levels of accuracy acceptable
for clinical use. We estimated the coverage of our predictor
at 57%, with a 95% confidence interval of 49%–64%. We
believe this level of coverage is still above the threshold
of clinical usefulness. For comparison, note that out of
350 LMM missense variants in the six target genes, only
74 met the criteria for high-confidence manual classifica-
tion, giving the manual classification process a coverage
of only 21%. Note also that our method covers a different
set of variants than the manual classification process,
including 59% of the variants that the manual classifica-
tion classifies as VUS.
The most important limitation of our automated predic-
tion method stems from the size of the training data set. In
general, training on small data sets may lead to overfitting
of automated classifiers. An overfit classifier may be highly
accurate on the training data but much less accurate on
new data. We applied several safeguards against overfitting
during training and validation. These included limiting
the number of features in the classifier, using only features
that we expected a priori to be informative, and perform-
ing cross validation to calibrate parameters and estimate
accuracy. In this way, we hope we have avoided excessive
overfitting in our final predictor.
It is important to point out that this method may not
accurately predict the effect of those missense variants
that exert their effect partially or fully though affecting
mRNA splicing. This is true for all currently available tools
of this kind, including PolyPhen-2, SIFT, and others. For
example, the MYBPC3 Glu258Lys variant was confidently190 The American Journal of Human Genetics 88, 183–192, Februarymanually classified as pathogenic but was incorrectly clas-
sified as benign in several runs of cross-validation (though
not in the final predictor). Many MYBPC3 variants affect
splicing, and there is evidence that the Glu258Lys variant
causes disease via this mechanism. The underlying cDNA
alteration is c.772>A, which affects the last base of
exon 6. This position is known to be part of the splice
consensus and five different splice predictors (SpliceSite-
Finder-like, MatEntScan, NNSPLICE, GeneSplicer, and
Human Splice Finder; see Figure S6) predict an impact on
splicing. This is supported by evidence showing that this
may result in skipping of exon 6.28,29 Therefore, the
conservation of the nucleotide and not the amino acid at
this position is essential, possibly explaining a mispredic-
tion by our predictor. This is a limitation of this method
and clearly lends itself to future improvement and genera-
tion of tools that incorporate a splice assessment.
It is also important to point out that clinical laboratories
are typically aware of this limitation. Novel variant assess-
ment is a lengthy and complex process that relies on a large
collection of different computer tools in combination with
traditional genetic evidence such as familial segregation
with disease and absence from race-matched healthy
controls. All evidence is taken into account to synthesize
a final probability for pathogenicity. In our laboratory,
a splice assessment is performed for everyvariant, regardless
of whether it changes an amino acid or not, and a benign
prediction by this predictor would not lead to a final classi-
ficationofbenign, particularlynot for genes forwhichpath-
ogenic splice variants are known to be common.
This example illustrates that this predictor or any other
predictor developed with this methodology should not be
used as a sole foundation for a diagnosis but rather be
used in combination with other lines of evidence in agree-
ment with recommendations from the American College
of Medical Genetics and the International Agency for
Research on Cancer.1,2 We envision future development of
a single probabilistic classifier that would automatically
combine heterogeneous factors such as familial segrega-
tion, frequency in controls, functional evidence, and
computationalpredictions followingearlywork in this area.Conclusion
We have addressed the problems that prevent automated
predictors from being widely used in genomic medicine
by developing a custom-tailored predictor specifically de-
signed for clinical use. Our analysis suggests several impor-
tant considerations that can increase the accuracy of
computational methods. Manual adjustment of multiple
sequence alignments and time-consuming computational
methods ofmolecular evolution are feasible when focusing
on a small set of genes and may improve predictions that
use comparative sequence analysis. Exploitation of specific
structural properties of proteins also becomes feasible
when focusing on a specific disease. Most importantly,11, 2011
a highly accurate manually curated data set is necessary to
train and validate an accurate predictor, and this level of
validation enables clinical laboratories to include it as
part of their variant assessment processes. Where previous
studies have concluded that existing tools are not mature
enough for clinical use, we believe that our tool is ready
for clinical use now, in combination with other sources
of information. Our collaborating clinical laboratory, the
LMM, has already begun to use our predictor as a source
of information about HCM variants, and we look forward
to helping additional laboratories do the same. Our study
focused on HCM, but we believe that our approach is
general and that analogous methods can be constructed
for many other diseases where genetic testing is an impor-
tant part of the diagnosis. In the future, we expect to work
with additional laboratories and on additional diseases to
expand the use of automated predictors in genomic medi-
cine and simplify the problem of interpreting novel
variants.Supplemental Data
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